Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Abliva Q3’20: Energizing Interactions

Niklas Elmhammer

2020-11-23

06:20

Redeye believes the key takeaway from the recent quarter is the positive momentum in clinical and regulatory development for lead candidate KL1333. Abliva has also initiated preliminary discussions with a US clinical trial regarding a possible collaboration for non-core asset NeuroSTAT.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Premium Plan required to unlock